This enduring accredited education will highlight the key points discussed in the virtual live activity. Global oncologists and gastroenterologists will receive education in selecting and managing treatment in later-line care for patients with mCRC a clinicians need updated guidance on strategies to optimize care with tyrosine kinase inhibitors (TKIs) in patients that have progressed after prior standard therapy, including current standard practices and new treatment options in development. This education will focus on improving treatment with TKIs in the 3rd-line setting for patients with mCRC. As a result of this microburst learning, learners should be better able to: 1. Explain the benefits of integrating the latest evidence into clinical practice for mCRC; 2. Review the latest data for tyrosine kinase inhibitors (TKIs) in the treatment of mCRC; and 3. Apply evidence-driven strategies to individualize later-line treatment selection for patients with mCRC. Downloadable slides and podcast are available to learners for use in clinical practice.
- Provider:Answers in CME Inc. (AiCME)
- Activity Link: https://www.answersincme.com/HFT
- Start Date: 2025-03-21 05:00:00
- End Date: 2025-03-21 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Bayer (Any division) - Amount: 85794.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Competence, Learner Knowledge
- Provider Ship: Directly Provided
- Registration: Open to all